Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Bingming Yi"'
Publikováno v:
Journal of Biopharmaceutical Statistics. :1-17
Autor:
Chenghao Chu, Bingming Yi
Publikováno v:
Journal of the Royal Statistical Society Series C: Applied Statistics. 70:1259-1280
In many clinical trials, especially trials in rare diseases or a certain population like paediatric, it is of great interest to incorporate historical data to increase power of evaluating the treatment effect of an experimental drug. In practice, his
Autor:
Daniel Parks, James Cooper, Rodrigo Refoios Camejo, Xiajun Ni, Hongxin Zhao, Yi Ning, Bingming Yi
Publikováno v:
Advances in Therapy. 36:1252-1265
To evaluate the comparative efficacy and safety of ropinirole and pramipexole as adjunctive therapies to levodopa (l-dopa) for the management of advanced Parkinson’s disease (PD), via a systematic review and network meta-analysis. Twenty-one double
Autor:
Gary A. Herman, Jon L. Ruckle, Ronald B. Langdon, Amy Qiu Wang, Keith Gottesdiener, Michael J. Davies, Bingming Yi, Goutam C. Mistry, John A. Wagner, Li Chen, Karen Snyder, Patrick Larson, Arthur J. Bergman, Wei Zeng
Publikováno v:
British Journal of Clinical Pharmacology. 71:429-436
AIMS Sitagliptin is a selective inhibitor of dipeptidyl peptidase-4 (DPP-4) used to treat type 2 diabetes. The present aim was to evaluate pharmacokinetic (PK), pharmacodynamic (PD) and safety characteristics of sitagliptin following single doses in
Autor:
Vernal R. Vaden, Janice A. Vasko, Lago Amparo M, John Fox, Sanjay Kumar, William F. Huffman, Maggie Schultz, Hyking Haley, James F. Callahan, Xiaoguang Liang, Bingming Yi, Theodore M. Danoff, Lorraine A. Fitzpatrick, M. Gowen, George B. Stroup, Nemeth Edward F, Christopher Matheny, Sandra J. Hoffman, Eric G. Delmar, Robert W. Marquis, Pradip K. Bhatnagar
Publikováno v:
Bone. 46:534-542
Daily subcutaneous administration of exogenous parathyroid hormone (PTH) promotes bone formation in patients with osteoporosis. Here we describe two novel, short-acting calcium-sensing receptor antagonists (SB-423562 and its orally bioavailable precu
Autor:
Mark Kipnes, Amy Qiu Wang, Deborah Hilliard, Kenneth C. Lasseter, John A. Wagner, Karen Snyder, Keith Gottesdiener, Wesley Tanaka, Bruno Dietrich, Jens J. Holst, Peng Zhao, Andreas Schrodter, Bart Keymeulen, Catherine Stevens, Carolyn F. Deacon, Kristien Van Dyck, Inge De Lepeleire, Caroline Cilissen, Arthur J. Bergman, Gary A. Herman, Wei Zeng, Marina De Smet, George Golor, Bingming Yi, Michael J. Davies, Paul Kotey, Michael Tanen
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 91:4612-4619
In response to a meal, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are released and modulate glycemic control. Normally these incretins are rapidly degraded by dipeptidyl peptidase-4 (DPP-4). DPP-4 inhibitors ar
Autor:
Arthur J. Bergman, Amy Qiu Wang, Deborah Hilliard, Gregory A. Winchell, Gary A. Herman, Wei Zeng, Marina De Smet, Michael J. Davies, Kristien Van Dyck, Cathy Stevens, Wesley Tanaka, Karen Snyder, D.G. Musson, Keith Gottesdiener, John A. Wagner, Steven Ramael, Michael Tanen, Bingming Yi
Publikováno v:
Clinical Pharmacology & Therapeutics. 78:675-688
Background Sitagliptin (MK-0431 [(2R)-4-oxo-4-(3-[trifluoromethyl]-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7[8H]-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine]) is an orally active, potent, and selective inhibitor of dipeptidyl peptidase IV (DPP-IV) cu
Publikováno v:
Journal of Chemical Information and Computer Sciences. 42:1221-1229
Drug discovery is dependent on finding a very small number of biologically active or potent compounds among millions of compounds stored in chemical collections. Quantitative structure-activity relationships suggest that potency of a compound is high
Publikováno v:
ChemInform. 33
Drug discovery is dependent on finding a very small number of biologically active or potent compounds among millions of compounds stored in chemical collections. Quantitative structure-activity relationships suggest that potency of a compound is high
Autor:
John A. Wagner, Arthur J. Bergman, Keith Gottesdiener, William K. Smith, Josee Cote, Gary A. Herman, Thomas Marbury, Suzanne K. Swan, Bingming Yi
Publikováno v:
Diabetes care. 30(7)
Sitagliptin is an oral, once-daily, potent, and highly selective dipeptidyl peptidase–4 inhibitor for the treatment of type 2 diabetes (1). In subjects with normal renal function (creatinine clearance >80 ml/min), 75–80% of an oral dose was excre